37 related articles for article (PubMed ID: 23085261)
21. CUTL1: a key mediator of TGFbeta-induced tumor invasion.
Michl P; Downward J
Cell Cycle; 2006 Jan; 5(2):132-4. PubMed ID: 16357536
[TBL] [Abstract][Full Text] [Related]
22. CUTL1 promotes tumor cell migration by decreasing proteasome-mediated Src degradation.
Aleksic T; Bechtel M; Krndija D; von Wichert G; Knobel B; Giehl K; Gress TM; Michl P
Oncogene; 2007 Aug; 26(40):5939-49. PubMed ID: 17369846
[TBL] [Abstract][Full Text] [Related]
23. CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness.
Michl P; Ramjaun AR; Pardo OE; Warne PH; Wagner M; Poulsom R; D'Arrigo C; Ryder K; Menke A; Gress T; Downward J
Cancer Cell; 2005 Jun; 7(6):521-32. PubMed ID: 15950902
[TBL] [Abstract][Full Text] [Related]
24. CUTL1 induces epithelial-mesenchymal transition in non-small cell lung cancer.
Wang J; Wang Y; Sun D; Ren F; Pang S; Xu S
Oncol Rep; 2017 May; 37(5):3068-3074. PubMed ID: 28405678
[TBL] [Abstract][Full Text] [Related]
25. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Liu ZM; Tseng JT; Hong DY; Huang HS
Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
[TBL] [Abstract][Full Text] [Related]
26. Multifaceted behavior of PEST sequence enriched nuclear proteins in cancer biology and role in gene therapy.
Sarfraz M; Afzal A; Khattak S; Saddozai UAK; Li HM; Zhang QQ; Madni A; Haleem KS; Duan SF; Wu DD; Ji SP; Ji XY
J Cell Physiol; 2021 Mar; 236(3):1658-1676. PubMed ID: 32841373
[TBL] [Abstract][Full Text] [Related]
27. Cutl1: a potential target for cancer therapy.
Liu KC; Lin BS; Zhao M; Wang KY; Lan XP
Cell Signal; 2013 Jan; 25(1):349-54. PubMed ID: 23085261
[TBL] [Abstract][Full Text] [Related]
28. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
[TBL] [Abstract][Full Text] [Related]
29. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).
Hafsi S; Pezzino FM; Candido S; Ligresti G; Spandidos DA; Soua Z; McCubrey JA; Travali S; Libra M
Int J Oncol; 2012 Mar; 40(3):639-44. PubMed ID: 22200790
[TBL] [Abstract][Full Text] [Related]
30. The role of HOPX in normal tissues and tumor progression.
Liu Y; Zhang W
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31934721
[TBL] [Abstract][Full Text] [Related]
31. The Widening Sphere of Influence of HOXB7 in Solid Tumors.
Errico MC; Jin K; Sukumar S; Carè A
Cancer Res; 2016 May; 76(10):2857-62. PubMed ID: 27197229
[TBL] [Abstract][Full Text] [Related]
32. Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics.
Krueger KE; Srivastava S
Mol Cell Proteomics; 2006 Oct; 5(10):1799-810. PubMed ID: 16844681
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
